Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound,…
Bristol Myers’ Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the…